Noen som følger med her?


Veloxis
INVESTOR RELATIONS
PRESS RELEASES
Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2019
August 8, 2019 at 5:47 PM CEST
PDF Version
Company Release no. 12/2019

To: NASDAQ Copenhagen A/S

Copenhagen, Denmark, 08 August 2019



Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2019



Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Interim Report for the first half of 2019. This Company Release should be read in conjunction with Veloxis’s full Interim Report for the first half of 2019, which is attached to this release and also available on Veloxis’s website at: http://www.veloxis.com.



Highlights


Product revenue for the first half of 2019 was USD 33.2 million, an increase of 94% compared with the same period last year.

US revenue increased 96% to USD 28.7 million
EU revenue increased 76% to USD 4.4 million

More than 95% of US transplant centers have utilized Envarsus® since its launch.

Veloxis reported a net income of USD 2.2 million for the first half of 2019 compared to a net loss of USD 5.7 million for the same period in 2018.


In connection with the Interim Report, Veloxis’s CEO, Craig Collard said:

“We are very pleased with the continued momentum we have experienced since receiving the de novo approval in December 2018. As previously announced, we have raised our outlook for 2019 based on stronger-than-expected sales of Envarsus XR in the US. I am confident in our ability to continue executing on our commercial strategy and expect the second half of 2019 to be just as successful as the first.”



Outlook for 2019

On 22 July 2019, Veloxis revised its 2019 Outlook of revenues to be in the range of USD 69-77 million and operating income before accounting for stock compensation in the range of USD 10-15 million. Veloxis previously reported its 2019 Outlook to be USD 58 – 68 million for revenues and operating income before accounting for stock compensation in the range of USD 4 – 10 million.
NilsAB
20.09.2019 kl 14:43 127

Begynner å røre på seg her igjen. Med fremdeles manko på Tacrolimus i medisinmarkedet tror jeg på fremdeles stor vekst fremover. Q3 er 11 november, og det er kanskje på tide å posisjonere seg...